Unanswered questions in cancer‐associated thrombosis
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18276
Abstract: Cancer‐associated venous thromboembolism (VTE) is a leading cause of morbidity and mortality in patients with cancer. Treatment of cancer‐associated VTE comes with a heightened risk of anticoagulant‐related bleeding that differs by choice of anticoagulant as… read more here.
Keywords: questions cancer; associated thrombosis; associated vte; cancer associated ... See more keywords
Direct oral anticoagulants and cancer-associated VTE: good for all, or just some?
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood.2019004177
Abstract: Venous thromboembolism (VTE) is associated with significant mortality and morbidity in patients with cancer. Therefore, tailoring anticoagulation is of utmost importance in order to decrease the risk of recurrent VTE while minimizing the risk of… read more here.
Keywords: oral anticoagulants; direct oral; associated vte; cancer associated ... See more keywords
The role of direct oral anticoagulants in venous thromboembolic disease in gynecologic cancer
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Gynecologic Oncology"
DOI: 10.3802/jgo.2020.31.e40
Abstract: https://ejgo.org The current treatment of choice for cancer-associated venous thromboembolism (VTE) is low molecular weight heparin. Of them, dalteparin is the only one that has been approved for use in cancer-associated VTE. There have been… read more here.
Keywords: gynecologic cancer; oral anticoagulants; direct oral; associated vte ... See more keywords